ABSTRACT
OBJECTIVE: Describe the epidemiological profile and social-economic burden that hydrocephalus patients represent to the national public health system, using data available at the online database of the Brazilian Health Ministry (DataSUS). METHODS: This is a populational study based on descriptive statistics of all clinical and surgical appointments included in the DataSUS database. Data included herein were collected between 2015 and 2021 and subdivided into three main groups, related to hydrocephalus incidence and mortality, hospitalizations, and financial costs. RESULTS: In the study period, 3993 new cases of congenital hydrocephalus were diagnosed, with 6051 deaths overall. The mortality rate in the country was 1.5/100000 live births and the prevalence was 0.374/100000 inhabitants. The number of hospitalizations resulting from treatment procedures and complications of hydrocephalus was 137,880 and there was a reduction of up to 27.2% during the SARS-CoV-2 pandemics concerning previous years. Total costs for hydrocephalus management in the country amounted to 140,610,585.51 dollars. CONCLUSIONS: Hydrocephalus has a significant impact on public health budgets and pediatric mortality rates; however, it is probably underestimated, due to the paucity of demographic data and epidemiological studies in Latin America and, specifically, in Brazil. The dataSUS also has several limitations in accessing certain data related to hydrocephalus, making it difficult to have a more assertive understanding of the disease in Brazil. The results of this study provide important guidance for future research projects in clinical and experimental hydrocephalus and also the creation of public policies for better governance and care of hydrocephalus patients.
Subject(s)
COVID-19 , Hydrocephalus , Humans , Child , Brazil/epidemiology , SARS-CoV-2 , Incidence , Hydrocephalus/epidemiologyABSTRACT
BACKGROUND: Myocarditis in context of a SARS-CoV-2 infection is vividly discussed in the literature. Real-world data however are sparse, and relevance of the myocarditis diagnosis to outcome in coronavirus disease (COVID-19) is unclear. PATIENTS AND METHODS: Retrospective analysis of 75,304 patients hospitalized in Germany with myocarditis between 2007 and 2020 is reported by DESTATIS. Patients hospitalized between 01/2016 and 12/2019 served as reference cohort for the COVID-19 patients hospitalized in 2020. RESULTS: A total of 75,304 patients were hospitalized between 2007 and 2020 (age 42.5 years, 30.1% female, hospital mortality 2.4%). In the reference cohort, 24,474 patients (age 42.8 years, 29.5% female, hospital mortality 2.2%) were registered. In 2020, annual myocarditis hospitalizations dropped by 19.6% compared to reference (4921 vs. 6119 annual hospitalization), of which 443/4921 (9.0%) were connected to COVID-19. In 2020, hospital mortality of myocarditis in non-COVID-19 patients increased significantly compared to reference (2.9% vs. 2.2%, p = 0.008, OR 1.31, 95% CI 1.08-1.60). In COVID-19 myocarditis, hospital mortality was even higher compared to reference (13.5% vs. 2.2%, p < 0.001, OR 6.93, 95% CI 5.18-9.18). CONCLUSION: The burden of patients with myocarditis and COVID-19 in 2020 was low. Hospital mortality was more than sixfold higher in patients with myocarditis and COVID-19 compared to those with myocarditis but without COVID-19.
ABSTRACT
INTRODUCTION AND OBJECTIVES: This article presents the data corresponding to implantable cardioverter-defibrillator (ICD) implantations in Spain in 2021. METHODS: The data were drawn from implanting centers, which voluntarily completed a data collection sheet during the procedure. RESULTS: In 2021, 7496 implant data sheets were received, compared with 7743 reported by Eucomed (European Confederation of Medical Suppliers Associations), indicating that data were collected from 96.8% of the devices implanted in Spain. Data completion ranged from 99.9% for "name of implanting hospital" to 8.9% for "implanting hospital". In 2021, 199 hospitals participated in the registry, exceeding the figures of previous years, with around 170 participating hospitals. The total rate of registered implants was 158/million inhabitants (163 according to Eucomed), making 2021 the year with the highest activity. However, the registry continues to show significant differences among the various autonomous communities and the lowest implantation rate of all the European countries participating in Eucomed. CONCLUSIONS: The Spanish implantable cardioverter-defibrillator registry for 2021 recorded an increase in the number of ICD implantations, reflecting the recovery of hospital activity after the initial impact of the COVID-19 pandemic in 2020. Although the total number of implants has increased in Spain, figures are still much lower than the European Union average, with differences persisting among Spanish autonomous communities.
ABSTRACT
Resumen Introducción y objetivos Se presentan los datos correspondientes a los implantes de desfibrilador automático implantable (DAI) en España en el año 2021. Métodos Los datos provienen de los centros implantadores, que cumplimentaron voluntariamente una hoja de recogida de datos durante el implante. Resultados En 2021 se recibieron 7.496 formularios de implante, frente a los 7.743 comunicadas por Eucomed (European Confederation of Medical Suppliers Associations), lo que implica que se han recogido datos del 96,8% de los dispositivos implantados en España. El cumplimiento osciló entre el 99,9% en el campo «nombre del hospital implantador» y el 8,9% en la variable «hospital de referencia». En 2021, 199 hospitales han participado en el registro, lo cual supera las cifras de los años previos en que el número de participantes osciló alrededor de 170 hospitales. La tasa total de implantes registrados fue 158/millón de habitantes (163 según Eucomed), lo que la sitúa como el año con mayor actividad. Sin embargo, el registro sigue mostrando diferencias importantes entre las comunidades autónomas y la tasa de implante más baja de todos los países europeos participantes en Eucomed. Conclusiones El Registro español de desfibrilador automático implantable del año 2021 recoge un incremento en el número de implantes de DAI y refleja la recuperación de la actividad hospitalaria tras el impacto inicial de la pandemia por COVID-19 durante 2020. A pesar del incremento en el número total de implantes en España, este sigue siendo muy inferior a la media de la Unión Europea y persisten las diferencias entre las comunidades autónomas españolas. Introduction and objectives This article presents the data corresponding to implantable cardioverter-defibrillator (ICD) implantations in Spain in 2021. Methods The data were drawn from implanting centers, which voluntarily completed a data collection sheet during the procedure. Results In 2021, 7496 implant data sheets were received, compared with 7743 reported by Eucomed (European Confederation of Medical Suppliers Associations), indicating that data were collected from 96.8% of the devices implanted in Spain. Data completion ranged from 99.9% for “name of implanting hospital” to 8.9% for “implanting hospital”. In 2021, 199 hospitals participated in the registry, exceeding the figures of previous years, with around 170 participating hospitals. The total rate of registered implants was 158/million inhabitants (163 according to Eucomed), making 2021 the year with the highest activity. However, the registry continues to show significant differences among the various autonomous communities and the lowest implantation rate of all the European countries participating in Eucomed. Conclusions The Spanish implantable cardioverter-defibrillator registry for 2021 recorded an increase in the number of ICD implantations, reflecting the recovery of hospital activity after the initial impact of the COVID-19 pandemic in 2020. Although the total number of implants has increased in Spain, figures are still much lower than the European Union average, with differences persisting among Spanish autonomous communities.
ABSTRACT
Resumen El presente registro aporta los datos correspondientes a la actividad de cirugía cardiovascular realizada en España durante el año 2020. Se trata de un registro anónimo y voluntario de datos agregados en el que han participado 60 hospitales del territorio nacional, transfiriendo sus datos a la Sociedad Española de Cirugía Cardiovascular y Endovascular (SECCE). Se comunican, por trigésimo segundo año consecutivo los datos de la actividad nacional. El de este año es, sin duda, un registro singular e importante para valorar el impacto que tuvo la pandemia de SARS-CoV-2 sobre la actividad en cirugía cardiaca en nuestro país, más allá de los datos que han sido ya comunicados en este sentido en diversos estudios comunicados por la SECCE. En el año 2020 comunicaron su actividad 60 hospitales frente a los 57 que compartieron datos en 2019. En total, se realizaron 27.017 intervenciones totales, con 17.880 procedimientos de cirugía cardiaca mayor. De estas, 15.534 procedimientos fueron realizados con circulación extracorpórea (CEC). Los 17.880 procedimientos de cirugía cardiaca mayor se pueden desglosar en 16.271 de enfermedad adquirida y 1.609 de enfermedad congénita. Además, se registraron 2.462 intervenciones de cirugía vascular periférica en los diferentes servicios de cirugía cardiovascular. Como en registros previos, tanto la cirugía cardiaca congénita como el trasplante cardiaco disponen de su propio registro. Dentro de los diferentes apartados de cirugía cardiaca mayor se realizaron: 6.766 procedimientos de cirugía univalvular aislada, 1.609 de cirugía valvular combinada, 4.219 procedimientos de revascularización, 1.912 de cirugía de aorta y 502 procedimientos de válvulas transcatéter (TAVI). En comparación con 2019, observamos un descenso generalizado de la actividad, siendo más marcado para la cirugía valvular (−21% para univalvular, −52% para TAVI transapical) y menos para cirugía coronaria (−11%). Además, informamos de diversos datos de distribución geográfica de la actividad quirúrgica a nivel nacional. The Spanish Society of Cardiovascular and Endovascular Surgery (SECCE) reports the results of the 2020 registry of the surgical activity in our country. This year represents the 33rd consecutive year in which this report is published. The participation in this registry is anonymous and voluntary, and it is based on the analysis of the information gathered from 60 centers with activity in cardiovascular surgery in our country, and the confidentiality of the individual data of each center is warranted. It is certainly an important issue in which COVID-19 impact on cardiac surgical activity is analysed. The registry reports the global activity in our country, the observed mortality and the estimated mortality risk, stratified in different types of procedures. In 2020, 27.017 interventions were performed, with 17.880 of major heart surgery. Among these, 16.271 procedures were adult cardiac surgery and 1.609 of congenital heart surgery. Congenital heart surgery and cardiac transplant registries are specifically analysed in their corresponding reports. Among the 17.311 procedures of acquired major cardiac surgery, isolated valve surgery was predominant (6.766 procedures), followed by coronary by-pass surgery (4.239), aorta surgery (1.902). TAVI procedures were performed in 502 cases. Coronary surgery showed a 11% decrease in activity. The information derived from this national registry allows to know the state-of-the-art of the surgical specialty in our country, through the knowledge of the surgical activity, the risk profile and the observed results, which is a keystone for an adequate evaluation of the quality of the health care that we deliver to the patients affected with cardiovascular pathologies. Risk adjusted mortality seems adequately adjusted, though important local differences are observed.
ABSTRACT
BACKGROUND: Cardiovascular complications of coronavirus disease 2019 (COVID-19) are critical for prognosis but have not been elucidated in Japan.MethodsâandâResults:The COVID-19 Registry Japan, which included data from 19,853 individuals at the end of 2020, was analyzed. The incidences of cardiovascular complications were 0.098% for myocarditis/pericarditis/cardiomyopathy, 0.48% for ventricular tachycardia/fibrillation, 0.17% for myocardial ischemia, 0.062% for endocarditis, 0.59% for deep vein thrombosis, 0.19% for pulmonary embolism, and 0.37% for cerebral infarction/hemorrhage. Excluding endocarditis, all complications were associated with increased in-hospital mortality. CONCLUSIONS: Cardiovascular complications of COVID-19 were infrequent in Japan but were associated with poor prognosis.
Subject(s)
COVID-19/complications , Cardiovascular Diseases/epidemiology , Adult , Aged , Aged, 80 and over , COVID-19/epidemiology , Cardiovascular Diseases/complications , Female , Hospitalization , Humans , Incidence , Japan/epidemiology , Male , Middle Aged , Registries , SARS-CoV-2ABSTRACT
PURPOSE: COVID-19 vaccines are currently undergoing long-term safety monitoring, including for ocular side effects. Uveitis following vaccination has been described previously with other vaccines and warrants evaluation for COVID-19 vaccines, especially given their widespread use. CASE REPORTS: We present two cases of patients who developed anterior uveitis following the Moderna COVID-19 vaccine, as reported to the National Registry for Drug-Induced Ocular Side Effects. We also summarize reports of anterior uveitis following COVID-19 vaccination as reported to the World Health Organization global database of individual case safety reports. CONCLUSIONS: Based on the temporal pattern of ocular inflammation following vaccine delivery in these cases, an association may be present between uveitis and COVID-19 vaccination. Further investigation to explore this association is warranted to guide patient care.
Subject(s)
COVID-19 Vaccines , COVID-19 , Uveitis, Anterior , Uveitis , Vaccines , Humans , 2019-nCoV Vaccine mRNA-1273 , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Uveitis/etiology , Uveitis, Anterior/chemically induced , Uveitis, Anterior/etiology , Vaccination/adverse effects , Vaccines/adverse effectsABSTRACT
The article provides an interim analysis of cases of COVID-19 reported as an occupational disease to the National Registry of Occupational Diseases in 2020 and in the 1st quarter of 2021. There were 370 cases, of which 285 are women representing 77% and 85 men representing 23%. The age range was from 18 to 70 years. The average age was 43 years. All the diseases occurred in 2020, mostly in the first wave of the epidemic. Because the average time between illness and the case reporting was 170 days, it can be expected that many cases are still under assessment. Most cases come from the Moravian-Silesian, Olomouc and Hradec Králové regions. Virtually all of these patients were infected during various health care or social work activities. They were mostly nurses, physicians, and other healthcare professionals. It is just tip of the iceberg. According to the Czech Medical Chamber, over 55 000 health professionals have contracted COVID-19 since the beginning of the epidemic until January 10, 2021. It is therefore essential that the first contact physicians thought about the possibility of the occupational origin of COVID-19, sufficiently informed their patients and referred them to the relevant occupational disease centers. Physicians should also initiate compensation for the families of workers who died of COVID-19. © 2021, University of Defence, Faculty of Military Health Sciences. All rights reserved.
ABSTRACT
INTRODUCTION AND OBJECTIVES: We present the data corresponding to implantable cardioverter-defibrillator (ICD) implants in Spain in 2020. METHODS: The data in this registry were drawn from implantation centers, which voluntarily completed a data collection sheet. RESULTS: In 2020, 7056 implant sheets were received compared with 7106 reported by Eucomed (European Confederation of Medical Suppliers Associations), indicating that data were collected from 99% of the devices implanted in Spain. Completion of the implant sheet ranged from 99.8% for the field "name of the implanting hospital" to 2.6% for the variable "referral hospital". A total of 173 hospitals performed ICD implants and participated in the registry, which is a similar figure to that in 2019 (n=172). The total rate of registered implants was 149/million inhabitants (150 according to Eucomed), revealing a slight reduction in implants in Spain in 2020 as a result of the impact of the COVID-19 pandemic. This reduction was uneven among the autonomous communities. CONCLUSIONS: The Spanish Implantable Cardioverter Defibrillator Registry for 2020 shows an improvement in the rate of implants reported and a reduction in the number of ICD implants, which likely reflects the decrease in hospital activity not related to the treatment of COVID-19 infection. Similar to previous years, the total number of implants in Spain is still much lower than the average for the European Union, with an increase in the differences between Spanish autonomous communities.
Subject(s)
COVID-19 , Cardiology , Defibrillators, Implantable , Arrhythmias, Cardiac/epidemiology , Arrhythmias, Cardiac/therapy , Humans , Pandemics , Registries , SARS-CoV-2ABSTRACT
COVID-19 pandemic has flooded all triage stations, making it difficult to carefully select those most likely infected. Data on total patients tested, infected, and hospitalized is fragmentary making it difficult to easily select those most likely to be infected. The Israeli Ministry of Health made public its registry of immediate clinical data and the respective status of infected/not infected for all viral DNA tests performed up to Apr. 18th, 2020 including almost 120,000 tests. We used a machine-learning algorithm to find out which immediate clinical elements mattered the most in identifying the true status of the tested persons including age or gender matter, to enable future better allocation of surveillance policy for those belonging to high-risk groups. In addition to the analyses applied on the first batch of the available data (Apr. 11th), we further tested the algorithm on the independent second batch (Apr. 12th to 18th). Fever, cough and headache were the most diagnostic, differing in degree of importance in different subgroups. Higher percentage of men were found positive (9.3 vs. 7.3%), but gender did not matter for the clinical presentation. The prediction power of the model was high, with accuracy of 0.84 and area under the curve 0.92. We provide a hand-held short checklist with verbal description of importance for the leading symptoms, which should expedite the triage and enable proper selection of people for further follow-up.